Regenerative Medicine Market in the US to grow at a CAGR of 33% during the 2016 - 2020, Finds New Report

Regenerative medicine deals with the process of using therapeutically-induced or laboratory grown human tissue to treat diseased or injured human cells, tissues, or organs. It is an emerging field of treatment that helps in producing new cells to substitute malfunctioning or injured cells as a vehicle to treat disease and injury. The regenerative medicine market can be characterized into three major modalities, namely tissue engineering, biomaterials/biomolecules, and stem cell therapy.

The market research analysts expect the regenerative medicine market in the US to grow at a fast pace, posting a remarkable CAGR of more than 33% during the forecast period because of the growing demand for tissue-engineered and stem cell products for the treatment of various diseases. The potential of these medicines in regenerating diseased organs is one of the major factors that drives the market in the US. The stem cells application and advancements in nanotechnology will further drive the progress in this market.

Segmentation by product and analysis of - cell therapy and scaffold

Cell therapy helps in treating the diseases or to improving the functioning of the existing cells, by administrating of cells into the body. This therapy addresses medical conditions related to the bone, cartilage, heart, skin, digestive system, reproductive system, eye, blood, spine, brain, and the nervous system. In 2015, cell therapy segment accounted for approximately 80% of the market share.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

• Cell therapy
• Scaffold

Segmentation by application and analysis of - dermatology, musculoskeletal, ocular, and cardiovascular

The year 2015 saw the precedence of the dermatology segment, accounting for a market share of more than 51%. Dermatology includes the treatment of burns and chronic wounds that requires a quick response, and skin grafting is essential in many cases. Factors such as the increase in obesity and diabetes, growing elderly population, and an increase in life expectancy are some of the causes contributing to the growth of the dermatology market.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

• Dermatology
• Musculoskeletal
• Ocular
• Cardiovascular

Competitive landscape and key vendors - AkzoNobel, Jotun, PPG

Regenerative medicine market in the US is highly competitive and fragmented because of the presence of several established vendors and this competitive environment is expected to intensify with advances in R&D and technological innovations. International players are likely to acquire regional or local players to enhance their products and expand their market share during the forecast period.

The top vendors in the market are -

• Acelity
• Mesoblast
• Organogenesis
• Reprocell
• Stryker

Other prominent vendors include  Aastrom Biosciences, Acologix, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Argos Therapeutics, Athersys, Avita Medical, Axogen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, BrainStorm Cell Therapeutics, Calimmune, Capricor, Celyad (Cardio3 BioSciences), Cell Medica, Cesca, CryoLife, Cynata Therapeutics, Cytori, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, Geron, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics P, Integra Life Sciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MaxCyte, Medtronics, Mesoblast, MiMedix Group, Nanofiber Solutions CTO, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa , Therapeutics, Organovo Holdings, Orteq, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, StemCells, Stratatech, TEI Biosciences, Tengion, Thermo Fischer Scientific, TiGenix, Tissue Genesis, TissueGene, VentriNova, Vericel, ViaCyte, Vistagen, and Zimmer.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the regenerative medicine market in the US?
• What are the key market trends impacting the growth of the regenerative medicine market in the US?
• What are the challenges to market growth?
• Who are the key vendors in the regenerative medicine market in the US?
• What are the market opportunities and threats faced by the vendors in the regenerative medicine market in the US?
• What are the key outcomes of the five forces analysis of the regenerative medicine market in the US?

Spanning over 77 pages, “Regenerative Medicine Market in the US 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Gene therapy: An emerging field in regenerative medicine, Pipeline portfolio, Regulatory scenario, Market landscape, Market segmentation by product, Market segmentation by application, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://mrr.cm/oDe

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

US Market for Bronchoscopic Devices - 2016, New Report Launched

Bronchoscopy is a minimally invasive procedure that screens the pulmonary tract for infections, tumors, bleeding or other abnormalities. These procedures may include retrieving sample tissue for biopsy, removing foreign material from the bronchi or for therapeutic applications such as dilating or stenting an obstructed airway. Rigid bronchoscopy is the traditional method of bronchoscopy; however, flexible bronchoscopy has been become the more popular type.

The U.S. market for ENT and bronchoscopic devices includes endoscopes, ENT powered instruments, radiofrequency (RF) devices, ENT hand instruments, sinus dilation devices, bronchial biopsy forceps and transbronchial aspiration (TBNA) needles, foreign body removal devices and bronchial hand instruments.  The ENT device market was driven by the continually strong ENT powered instrument and RF device segments, in addition to the rapidly growing balloon sinus dilation (BSD) segment. The bronchoscopic device market was driven by the bronchoscope, bronchial forcep and TBNA needle segments.

Spanning over 135 pages “US Market for Bronchoscopic Devices - 2016” report covers Executive Summary, Research Methodology, Bronchoscopy Device Market Overview, Bronchoscopy Procedure Numbers, Bronchoscope Market, Bronchoscopic Hand Instrument Market, Bronchial Stent Market, Bronchial Forceps And Transbronchial Aspiration Needle Market, Foreign Body Removal Device Market. The Report covered companies are - Boston Scientific, Olympus, ConMed, Pentax, Karl Storz, Merit Medical EndoTek, Fujinon, Bryan Corporation, Teleflex, Boston Medical Products, Integra LifeSciences, Richard Wolf, Hood Laboratories, Cook Medical, Instrumentarium

For more information Visit at: http://mrr.cm/oD3

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Global Drugs for Chronic Cough Industry 2015 Market Report; Launched via MarketResearchReports.com

The Global Drugs for Chronic Cough Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Drugs for Chronic Cough industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Drugs for Chronic Cough market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.The Drugs for Chronic Cough industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 167 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Spanning over 154 pages “Global Drugs for Chronic Cough Industry 2015 Market Research Report” report covers Industry Overview, Manufacturing Cost Structure Analysis of Drugs for Chronic Cough, Technical Data and Manufacturing Plants Analysis of Drugs for Chronic Cough, Production Analysis of Drugs for Chronic Cough by Regions, Type, and Applications, Consumption Volume and Consumption Value Analysis of Drugs for Chronic Cough by Regions, Analysis of Drugs for Chronic Cough Production, Supply, Sales and Market Status 2010-2015, Analysis of Drugs for Chronic Cough Industry Key Manufacturers, Price and Gross Margin Analysis of Drugs for Chronic Cough, Marketing Trader or Distributor Analysis of Drugs for Chronic Cough, Development Trend of Drugs for Chronic Cough Industry 2016-2021, Industry Chain Suppliers with Contact Information of Drugs for Chronic Cough, New Project Investment Feasibility Analysis of Drugs for Chronic Cough, Conclusion of the Europe Drugs for Chronic Cough Industry 2015 Market Research Report.

For more information Visit at: http://mrr.cm/oRz

Related Report:

Global Drugs for Cough Industry 2015 Market Research Report - visit at: http://mrr.cm/oRK

Global HIV Therapeutics Market Value Will Crawl to Almost $15.3 Billion by 2023, Finds New Report

The Human Immunodeficiency Virus (HIV) treatment landscape is expected to experience a paradigm shift towards integrase inhibitor drugs and single-tablet regimens (STRs).  The market growth will mainly be driven by the introduction of novel drugs, such as STRs with improved tolerability, a reduced pill burden or increased efficacy, and an increasing number of people living with HIV who are treated with antiretroviral therapy (ART).

However, due to patient and physician awareness of HIV often being limited, there have been low diagnosis rates, increased disease transmission, and delayed ART administration. Furthermore, several countries, such as Germany, China and Brazil, will promote the use of more affordable generic drugs over branded products.

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023 report provides analysis of global Human Immunodeficiency Virus (HIV) therapeutics market across the nine major countries of the US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China. It includes annualized HIV treatment market data from 2013 and forecast to 2023, as well as a review of the key industry drivers, restraints and challenges.

Key questions answered:

• How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2013–2023?
• What are the most promising late-stage pipeline drugs in HIV?
• How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
• What are the unmet needs in HIV treatment management?
• What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Key Findings

• The global HIV therapeutics market was worth approximately $14 billion in 2013, and Publisher projects this market to reach a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These sales are expected to come predominantly from the US market, as financial austerity measures remain a primary barrier to the growth of the HIV market in the other countries covered in this report.
• Over Publisher’s 2013-2023 forecast period, the increased uptake of STRs is expected to drive market growth. KOLs interviewed by Publisher expect that INI-based STRs - led by ViiV’s Triumeq and Gilead’s Quad 2 - will dominate the marketplace for the duration of the forecast period.
• The most notable barriers of growth over the forecast period include patent expiries of key HIV drugs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan) and compulsory licensing in Brazil and China.

For more information Visit at: http://mrr.cm/oDq

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases